Monopar Therapeutics
MNPR
12 hedge funds and large institutions have $533K invested in Monopar Therapeutics in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0.32% → 0.32% (-0%)
8% less funds holding
Funds holding: 13 → 12 (-1)
19% less capital invested
Capital invested by funds: $657K → $533K (-$124K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.43K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$1.48K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$118 |
| 4 |
Morgan Stanley
New York
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$2.11K |
| 2 |
BlackRock
New York
|
-$1.66K |
| 3 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $255K | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $100K | – | – | – |
|
|
3
Northern Trust
Chicago,
Illinois
| $90K | -$2.11K | -143 | -2% |
|
|
4
BlackRock
New York
| $35K | -$1.66K | -112 | -4% |
|
|
IA
5
IFP Advisors
Tampa,
Florida
| $13K | +$1.48K | +100 | New |
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $10K | – | – | – |
|
|
7
Morgan Stanley
New York
| $10K | +$15 | +1 | +0.1% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $9K | +$3.43K | +232 | +48% |
|
|
9
UBS Group
Zurich,
Switzerland
| $8K | +$118 | +8 | +1% |
|
|
APA
10
American Portfolios Advisors
Holbrook,
New York
| $1.78K | – | – | – |
|
|
FCA
11
FinTrust Capital Advisors
Greenville,
South Carolina
| $1K | – | – | – |
|
|
12
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -34 | Closed |
|
MNPR Hedge Fund Activity: Q1 2022 in Review
12 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q1 2022, worth a combined $533K — down 19% from $657K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of MNPR and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $3.43K. The largest seller was Northern Trust, cutting an estimated $2.11K.
- 12 institutional investors held Monopar Therapeutics (MNPR) as of Q1 2022, down from 13 in Q4 2021.
- Funds reported $533K of Monopar Therapeutics stock for Q1 2022, down 19% quarter-over-quarter.
- 1 fund opened new Monopar Therapeutics positions in Q1 2022 and 2 closed out, a net change of -1 holder.
- The largest Monopar Therapeutics buyer in Q1 2022 was Tower Research Capital (TRC), an estimated $3.43K added.
- The largest Monopar Therapeutics seller in Q1 2022 was Northern Trust, an estimated $2.11K sold.
Based on aggregated 13F filings for Q1 2022.